Gender-Differentiated Impact of Long-Term PPI Use on Bone Density and Microarchitecture
Overview
Chronic proton pump inhibitor (PPI) use is associated with degraded trabecular bone quality and reduced bone mineral density (BMD) in men, but not in women. This study, analyzing NHANES data, highlights significant sex-specific differences in the skeletal effects of long-term PPI therapy.
Background
Proton pump inhibitors are widely prescribed for acid-related disorders and generally well tolerated. However, concerns have emerged regarding their long-term adverse effects, including increased fracture risk. While fracture risk elevation with PPI use is well documented, the impact on bone mineral density remains unclear, with conflicting evidence. Bone quality, assessed by trabecular bone score (TBS), offers additional insight into skeletal fragility beyond BMD, but data on PPI effects on TBS are limited.
Data Highlights
Parameter
Men (PPI Users vs Non-Users)
Women (PPI Users vs Non-Users)
TBS Difference
-0.039 (95% CI: -0.058 to -0.020; P < .001)
No significant difference
Lumbar Spine T-score
-0.27 (95% CI: -0.51 to -0.04; P = .023)
No significant difference
Total Hip T-score
-0.21 (95% CI: -0.41 to -0.01; P = .041)
No significant difference
Femoral Neck T-score
-0.22 (95% CI: -0.44 to -0.00; P = .047)
No significant difference
TBS adjusted for BMD
-0.026 (95% CI: -0.039 to -0.012; P = .001)
Not significant
Key Findings
Chronic PPI use is significantly associated with lower trabecular bone score (TBS) in men, indicating degraded bone microarchitecture.
Men using PPIs show significantly reduced bone mineral density at lumbar spine, total hip, and femoral neck compared to non-users.
The association between PPI use and degraded TBS in men remains significant even after adjusting for BMD, suggesting independent effects on bone quality.
No significant associations between chronic PPI use and either TBS or BMD were observed in women.
The study utilized a large, representative sample from NHANES (7478 subjects) and adjusted for multiple confounders.
Clinical Implications
Clinicians should be aware of the potential adverse effects of long-term PPI use on bone health in men, including both bone density and microarchitectural integrity. Monitoring bone quality using TBS alongside BMD may provide a more comprehensive assessment of fracture risk in male patients on chronic PPI therapy. In women, PPI use does not appear to significantly impact bone density or quality, suggesting sex-specific management strategies may be warranted.
Conclusion
Long-term PPI use is linked to impaired trabecular bone microarchitecture and reduced bone mineral density in men but not in women, underscoring the importance of sex-specific evaluation in assessing PPI-related skeletal risks.
References
NHANES 2005-2008 Data -- National Health and Nutrition Examination Survey
FDA 2010 -- Updated PPI Side Effects Including Fracture Risk
Trabecular Bone Score Studies -- Bone Quality Assessment
